Terms: = Pancreatic cancer AND ATRX, P46100, ZNF-HX, XNP, XH2, SHS, SFM1, RAD54, MRXHF1, MGC2094, ATR2, 546 AND Treatment
43 results:
1. Multiregion WES of metastatic pancreatic neuroendocrine tumors revealed heterogeneity in genomic alterations, immune microenvironment and evolutionary patterns.
Jiang Y; Dong YH; Zhao SW; Liu DY; Zhang JY; Xu XY; Chen H; Chen H; Jin JB
Cell Commun Signal; 2024 Mar; 22(1):164. PubMed ID: 38448900
[TBL] [Abstract] [Full Text] [Related]
2. Effect of laparoscopic and open distal pancreatectomy on postoperative wound complications in patients with pancreatic cancer: A meta-analysis.
Hong C; Liu W
Int Wound J; 2024 Feb; 21(2):e14708. PubMed ID: 38351522
[TBL] [Abstract] [Full Text] [Related]
3. DAXX promotes centromeric stability independently of atrx by preventing the accumulation of R-loop-induced DNA double-stranded breaks.
Pinto LM; Pailas A; Bondarchenko M; Sharma AB; Neumann K; Rizzo AJ; Jeanty C; Nicot N; Racca C; Graham MK; Naughton C; Liu Y; Chen CL; Meakin PJ; Gilbert N; Britton S; Meeker AK; Heaphy CM; Larminat F; Van Dyck E
Nucleic Acids Res; 2024 Feb; 52(3):1136-1155. PubMed ID: 38038252
[TBL] [Abstract] [Full Text] [Related]
4. A review of functional pancreatic neuroendocrine tumors: Exploring the molecular pathogenesis, diagnosis and treatment.
Alshareefy Y; Cummins S; Mazzoleni A; Sharma V; Guggilapu S; Leong AWY; Wireko AA
Medicine (Baltimore); 2023 Nov; 102(46):e36094. PubMed ID: 37986400
[TBL] [Abstract] [Full Text] [Related]
5. A nomogram for preoperative prediction of microvascular invasion in ruptured hepatocellular carcinoma.
Xia F; Zhang Q; Ndhlovu E; Zheng J; Gao H; Xia G
Eur J Gastroenterol Hepatol; 2023 May; 35(5):591-599. PubMed ID: 36966771
[TBL] [Abstract] [Full Text] [Related]
6. Aggressive versus indolent insulinomas: new clinicopathological insights.
Hackeng WM; Brosens LAA; Dreijerink KMA
Endocr Relat Cancer; 2023 May; 30(5):. PubMed ID: 36779771
[TBL] [Abstract] [Full Text] [Related]
7. Reprint of: The Diagnostic and Prognostic Utility of Incorporating DAXX, atrx, and Alternative Lengthening of Telomeres (ALT) to the Evaluation of pancreatic Neuroendocrine Tumors (PanNETs).
Heaphy CM; Singhi AD
Hum Pathol; 2023 Feb; 132():1-11. PubMed ID: 36702689
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic and Predictive Biomarkers for pancreatic Neuroendocrine Tumors.
Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
[TBL] [Abstract] [Full Text] [Related]
9. The diagnostic and prognostic utility of incorporating DAXX, atrx, and alternative lengthening of telomeres to the evaluation of pancreatic neuroendocrine tumors.
Heaphy CM; Singhi AD
Hum Pathol; 2022 Nov; 129():11-20. PubMed ID: 35872157
[TBL] [Abstract] [Full Text] [Related]
10. Accurate Nodal Staging in pancreatic cancer in the Era of Neoadjuvant Therapy.
Javed AA; Ding D; Baig E; Wright MJ; Teinor JA; Mansoor D; Thompson E; Hruban RH; Narang A; Burns WR; Burkhart RA; Lafaro K; Weiss MJ; Cameron JL; Wolfgang CL; He J
World J Surg; 2022 Mar; 46(3):667-677. PubMed ID: 34994834
[TBL] [Abstract] [Full Text] [Related]
11. Pre-operative radiomics model for prognostication in resectable pancreatic adenocarcinoma with external validation.
Healy GM; Salinas-Miranda E; Jain R; Dong X; Deniffel D; Borgida A; Hosni A; Ryan DT; Njeze N; McGuire A; Conlon KC; Dodd JD; Ryan ER; Grant RC; Gallinger S; Haider MA
Eur Radiol; 2022 Apr; 32(4):2492-2505. PubMed ID: 34757450
[TBL] [Abstract] [Full Text] [Related]
12. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs.
Shi M; Fan Z; Xu J; Yang J; Li Y; Gao C; Su P; Wang X; Zhan H
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188637. PubMed ID: 34678439
[TBL] [Abstract] [Full Text] [Related]
13. The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms.
Venizelos A; Elvebakken H; Perren A; Nikolaienko O; Deng W; Lothe IMB; Couvelard A; Hjortland GO; Sundlöv A; Svensson J; Garresori H; Kersten C; Hofsli E; Detlefsen S; Krogh M; Sorbye H; Knappskog S
Endocr Relat Cancer; 2021 Nov; 29(1):1-14. PubMed ID: 34647903
[TBL] [Abstract] [Full Text] [Related]
14. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets.
van Riet J; van de Werken HJG; Cuppen E; Eskens FALM; Tesselaar M; van Veenendaal LM; Klümpen HJ; Dercksen MW; Valk GD; Lolkema MP; Sleijfer S; Mostert B
Nat Commun; 2021 Jul; 12(1):4612. PubMed ID: 34326338
[TBL] [Abstract] [Full Text] [Related]
15. Sunitinib and Evofosfamide (TH-302) in Systemic treatment-Naïve Patients with Grade 1/2 Metastatic pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.
Grande E; Rodriguez-Antona C; López C; Alonso-Gordoa T; Benavent M; Capdevila J; Teulé A; Custodio A; Sevilla I; Hernando J; Gajate P; Molina-Cerrillo J; Díez JJ; Santos M; Lanillos J; García-Carbonero R
Oncologist; 2021 Nov; 26(11):941-949. PubMed ID: 34190375
[TBL] [Abstract] [Full Text] [Related]
16. Platinum-Based treatment for Well- and Poorly Differentiated pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract] [Full Text] [Related]
17. Do Canine pancreatic Neuroendocrine Neoplasms Resemble Human pancreatic Neuroendocrine Tumours? A Comparative Morphological and Immunohistochemical Investigation.
de Vries C; Konukiewitz B; Weichert W; Klöppel G; Aupperle-Lellbach H; Steiger K
J Comp Pathol; 2020 Nov; 181():73-85. PubMed ID: 33288156
[TBL] [Abstract] [Full Text] [Related]
18. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies.
Arakelyan J; Zohrabyan D; Philip PA
Cancer; 2021 Feb; 127(3):345-353. PubMed ID: 33270905
[TBL] [Abstract] [Full Text] [Related]
19. A methylomics-associated nomogram predicts recurrence-free survival of thyroid papillary carcinoma.
Chen H; Ma X; Yang M; Wang M; Li L; Huang T
Cancer Med; 2020 Oct; 9(19):7183-7193. PubMed ID: 32783399
[TBL] [Abstract] [Full Text] [Related]
20. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract] [Full Text] [Related]
[Next]
